Lakefront Biotherapeutics reports September 21 to 25 buyback, holdings reach 1,633,594 shares
The latest weekly repurchase under the company's June 9, 2026 program brought its holding of own shares to 1,633,594.
SEC filing (8)
Latest
6 stories
Tuesday, September 29
Tuesday, August 25
FDA grants orphan drug status to Lakefront's gamgertamig for pemphigus
The designation adds to earlier Fast Track and Orphan Drug status the drug already holds for two other autoimmune blood disorders.
SEC filing
Monday, August 24
ANI Pharmaceuticals adds Henry Gosebruch to board, Shanmugam resigns directorship
The rare disease-focused drugmaker named a longtime AbbVie strategy executive to its board effective August 19, 2026, as a current director stepped down from the board while keeping his executive role.
SEC filing
Wednesday, August 12
Lakefront reports H1 2026 results after closing Ouro Medicines deal with Gilead
The company said it expects at least €1.6 billion in cash to remain after funding its lead program, gamgertamig, to first approval.
SEC filing
Tuesday, August 4
Lakefront Biotherapeutics discloses six weeks of share buybacks through July 31
The company reported repurchasing nearly 588,000 shares for about €15.1 million since late June under a program announced June 9, 2026.
SEC filing (6)
Monday, July 13
Lakefront board member Fontoura resigns after Sanofi names him R&D chief
Paulo Fontoura steps down from Lakefront Biotherapeutics' board following his appointment to a top research role at Sanofi.
SEC filing